Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale

13 August 2026 · By · Wire by Fusion42

Published

13 August 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 22 August 2026 · Fusion42 review

Bankrupt Sangamo Therapeutics has sold its assets in a $161 million deal where PTC Therapeutics won the bid for Sangamo's Fabry disease gene therapy, and Eli Lilly acquired its prion disease program and additional platforms.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your biotech venture faces a new potential buyer landscape as notable players like Eli Lilly and PTC Therapeutics are expanding by absorbing distressed assets; expect intensified competition and partnership opportunities in gene therapy and rare diseases.

◆ Coverage

1 source · 13 Aug 2026

◆ Related on Wire

◆ Topics

Biotechbankruptcyasset-salebiotechgene-therapystrategic-acquisition